HALO vs HCA · P/E 15, rev $857.7M vs P/E 17, rev $75.60B
Halozyme Therapeutics Inc (HALO) versus HCA Holdings Inc (HCA) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
HCA Holdings Inc (HCA) is a medical care facilities company listed on US.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Latest reported HCA revenue for 2025-12-31 was $75.60B. Net income was $6.78B. Revenue was up 7.1% from 2024-12-31 to 2025-12-31. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. HCA currently screens at market cap $91.01B and trailing P/E 16.8.
Not investment advice. Open the HALO and HCA stock pages for the full models.
Not investment advice.